NCT00239317 is a Phase 3 clinical trial of Tamusulosin in Urinary Tract Diseases, sponsored by Astellas Pharma Inc.

Who is sponsoring NCT00239317?

NCT00239317 is sponsored by Astellas Pharma Inc.

What drugs are being tested in NCT00239317?

Interventions in NCT00239317: Tamusulosin.

What condition does NCT00239317 study?

NCT00239317 studies Urinary Tract Diseases.

Is NCT00239317 still recruiting?

NCT00239317 is currently completed. Last updated 18 October 2007.

Last reviewed 2007-10-18 · How we verify

NCT00239317

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome

Completed Phase 3 Last updated 18 October 2007

What this trial tests

Phase 3 trial testing Tamusulosin in Urinary Tract Diseases. Completed.

Quick facts

Lead sponsor	Astellas Pharma Inc
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Sites	7 locations across Japan

Drugs / interventions tested

Tamusulosin — full drug profile →

Conditions studied

Urinary Tract Diseases — all drugs for Urinary Tract Diseases →

Sponsor

Astellas Pharma Inc — full company profile →

Who can join

Adults 20 to 90, male only, with Urinary Tract Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether Tamusulosin is effective in the treatment of lower urinary tract syndrome with male patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Astellas Pharma Inc trials

Trials by the same sponsor.

NCT07318714 — A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke · Phase 1, PHASE2 · recruiting
NCT07094204 — A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors · Phase 1 · recruiting
NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
NCT06364696 — A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors · Phase 1 · active not recruiting
NCT06206421 — A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00239317 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Inc
Last refreshed: 18 October 2007

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00239317.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing